Denosumab effect on bone mineral density and urinary-NTX in breast cancer patients receiving aromatase inhibitors.

Masahiro ShibataMai OkumuraShin KawanoHirotoshi NodaChihiro ToyotaYutaka Mizuno

Published in: Journal of bone and mineral metabolism (2023)

Denosumab increased BMD in patients treated with aromatase inhibitors. The u-NTX level decreased soon after start of denosumab treatment, and its change ratio is predictive of improvement in BMD.

Keyphrases

bone mineral density
postmenopausal women
body composition
combination therapy
replacement therapy
breast cancer risk